ALLR
Allarity TherapeuticsALLR
ALLR
About: Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States.
Employees: 7
0
Funds holding %
of 7,407 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
165% more capital invested
Capital invested by funds: $46.1K [Q3] → $122K (+$76.1K) [Q4]
67% more funds holding
Funds holding: 3 [Q3] → 5 (+2) [Q4]
0.81% more ownership
Funds ownership: 1.55% [Q3] → 2.36% (+0.81%) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for ALLR.
Financial journalist opinion
Based on 3 articles about ALLR published over the past 30 days
Neutral
PRNewsWire
5 days ago
ALLR Shareholders are Encouraged to Join Allarity Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm
LOS ANGELES , April 14, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allarity Therapeutics, Inc. ("Allarity" or "the Company") (NASDAQ: ALLR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Neutral
PRNewsWire
3 weeks ago
ALLR Shareholders are Encouraged to Join Allarity Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm
LOS ANGELES , March 25, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allarity Therapeutics, Inc. ("Allarity" or "the Company") (NASDAQ: ALLR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Neutral
Accesswire
4 weeks ago
Shareholder Rights Advocates at Levi & Korsinsky Investigate Allarity Therapeutics, Inc. (ALLR) Regarding Possible Securities Fraud Violations
NEW YORK, NY / ACCESS Newswire / March 21, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Allarity Therapeutics, Inc. ("Allarity Therapeutics, Inc.") (NASDAQ:ALLR) concerning possible violations of federal securities laws. On July 22, 2024, Allarity filed a current report on Form 8-K with the SEC.
Neutral
Accesswire
1 month ago
Levi & Korsinsky Announces an Investigation on Behalf of Allarity Therapeutics, Inc. (ALLR) Shareholders Who May Have Been Affected by Fraud
NEW YORK, NY / ACCESS Newswire / March 19, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Allarity Therapeutics, Inc. ("Allarity Therapeutics, Inc.") (NASDAQ:ALLR) concerning possible violations of federal securities laws. On July 22, 2024, Allarity filed a current report on Form 8-K with the SEC.
Neutral
PRNewsWire
1 month ago
ALLR Shareholders are Encouraged to Join Allarity Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm
LOS ANGELES , March 19, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allarity Therapeutics, Inc. ("Allarity" or "the Company") (NASDAQ: ALLR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Neutral
PRNewsWire
1 month ago
ALLR Investors Have Opportunity to Join Allarity Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm
LOS ANGELES , March 14, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allarity Therapeutics, Inc. ("Allarity" or "the Company") (NASDAQ: ALLR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Neutral
GlobeNewsWire
1 month ago
Allarity Therapeutics Announces Final Settlement with the U.S. Securities and Exchange Commission
Boston (March 13, 2025)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated dual PARP/Wnt pathway inhibitor—today announced that it has reached a final settlement with the U.S. Securities and Exchange Commission (SEC) relating to the previously disclosed investigation regarding the Company's past disclosures concerning its interactions with the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (“NDA”) for Dovitinib or Dovitinib-DRP, which was submitted to the FDA in 2021. This final settlement confirms the settlement in principle announced by the Company on January 30, 2025.
Neutral
GlobeNewsWire
1 month ago
Allarity Therapeutics Announces Phase 2 Trial of Stenoparib in Combination with Temozolomide for Recurrent Small Cell Lung Cancer Fully Funded by the US Veterans Administration
Boston (March 6, 2025)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated dual PARP/Wnt pathway inhibitor—today announced plans for a Phase 2 trial evaluating the combination of stenoparib with temozolomide, a DNA-alkylating chemotherapy agent, for the treatment of recurrent Small Cell Lung Cancer (SCLC). The trial is fully funded by the U.S. Veterans Administration (VA) through the Special Emphasis Panel on Precision Oncology and is being led by the VA and Academic Medical Oncologists at Indianapolis and Pittsburgh VA Medical Centers.
Neutral
GlobeNewsWire
1 month ago
Allarity Therapeutics Announces Dismissal of Securities Class Action Lawsuit
Boston (February 26, 2025)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated dual PARP/Wnt pathway inhibitor—as a personalized cancer treatment using its proprietary, drug-specific patient selection technology—the Drug Response Predictor (DRP®)—today announced that the securities class action lawsuit in the United States District Court for the Southern District of New York referenced in the Company's Form 10-Q filing on November 11, 2024, has been dismissed in whole against all defendants.
Neutral
GlobeNewsWire
1 month ago
Allarity Therapeutics to Begin Enrollment for New Phase 2 Protocol to Advance Stenoparib Toward FDA Approval in Advanced Ovarian Cancer Patients
Boston (February 24, 2025)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated dual PARP/Wnt pathway inhibitor—as a personalized cancer treatment using its proprietary, drug-specific patient selection technology—the Drug Response Predictor (DRP®)—today announced that the new protocol for its Phase 2 clinical trial of stenoparib in ovarian cancer is set to begin and will be expected to provide critical data by end of summer 2026 for a pivotal registration trial.
Charts implemented using Lightweight Charts™